利妥昔单克隆抗体时代中期18~F-FDG PET/CT在弥漫大B细胞淋巴瘤中的应用价值研究进展  

Role of Interim 18~F-FDG PET/CT Scanning for Diffuse Large B Cell Lymphoma in Rituximab Era

作　　者：陆晓林[1] 朱海燕[1] 于力[1] 

机构地区：[1]中国人民解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2017年第4期1241-1244,共4页Journal of Experimental Hematology

摘　　要：正电子放射断层造影术-计算机断层摄影术(positron emission tomography-computed tomography,PET/CT)作为一种重要的无创性检查手段,在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)诊治过程中的作用举足轻重。在利妥昔单克隆抗体时代,PET/CT已替代传统CT检查,成为初诊患者精确分期和治疗过程中评估疗效的标准影像学检查。本文通过介绍中期PET/CT的定义、判读方法、预后价值及危险度分层来阐明中期PET/CT在DLBCL诊治过程中的驱动意义,并对近年来关于中期PET/CT驱动的治疗调整在临床中的应用进行综述。As an important noninvasive diagnostic tool,the positron emission tomography/computed tomography（ PET/CT） plays a significant role in diagnosis and therapy of patients with diffuse large B-cell lymphoma（ DLBCL）.PET/CT,a standard imaging tool for initial accurate staging and response assessments,has replaced conventional CT in rituximab era. In this review,the definition,interpretation method,prognostic value and risk stratification of interim PET/CT are introduced to clarify the guiding significance of PET/CT in the diagnosis and theray of DLBCL,and the application of PET/CT scanning-guided prognostic factors and response-adapted therapy for DLBCL is summarized.

关 键 词：中期PET/CT 弥漫大B细胞淋巴瘤 治疗调整 利妥昔单克隆抗体时代 

分 类 号：R733.1[医药卫生—肿瘤]